Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-1: Orforglipron in Adults With Obesity or Overweight
NCT05869903Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of orforglipron in obesity, Overweight, sponsored by Eli Lilly and Company. Started Jun 2023; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05869903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869903.